Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

NCT04189848 · Completed

Last updated 2026-05-28

This clinical trial compares the pain experienced at the injection site between semaglutide and dulaglutide in healthy volunteers, people with type 2 diabetes, and those who are overweight or obese.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 104 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2019-12 · est. completion 2020-02

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT04189848 ↗

Description as written by the study sponsor.

This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Treatments tested

Semaglutide Drug

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.
Dulaglutide Drug

Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.

Main thing measured	Intensity of Injection Site Pain
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
GLP-1 drugs	semaglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04189848 ↗